NTT Precision Medicine

What NTT Precision Medicine does

NTT Precision Medicine Corporation (NTTプレシジョンメディシン株式会社) is a Japanese precision medicine company wholly owned by Nippon Telegraph and Telephone Corporation (NTT), established on July 1, 2019 with 400 million yen in capital and headquartered in Tokyo's Otemachi First Square. The company operates a B2B2C and direct-to-consumer model in which genetic testing services are delivered either through corporate wellness programs (健康経営) tied to employer health checkups, or through a network of 76 partner medical institutions (as of July 2026) where individuals receive testing at the point of care, with results delivered through a d-account-registered web portal.

The core product suite is anchored by the Genovision® brand, comprising Genovision Dock® (SNP-based disease risk profiling across ~90 conditions using Illumina's Asian Screening Array of ~650,000 markers, with ~97% genotyping accuracy) and Genovision PGx (pharmacogenomics testing of 18 drug-response genes via RIKEN-licensed corePGseq technology, covering ~70 medications under JCPIC interpretation guidelines). Supporting products include the Japan Precision Medicine Platform® (JPP) for integrated clinical, examination, and genomic data analysis; the NTT Cohort service for research using genomic, health checkup, and claims data; a Specified Health Guidance Service using Abbott FreeStyle Libre 2 continuous glucose monitoring; the Mobacaru Hospital cloud-based electronic medical record system (which added an AI document creation feature in June 2026); and corporate health management consulting plus a set of training programs. Analytical genotyping operations are handled by Genesis Healthcare under a partnership effective June 2023.

Revenue is generated through enterprise contracts with corporations for employee genetic testing and health management consulting (treated as subscription/recurring and professional services), per-test fees at partner medical institutions, cohort and data licensing arrangements with research institutions, and EMR subscription fees. The company holds ISO/IEC 27001:2022 and Privacy Mark certifications, conducts all testing domestically, and maintains joint research relationships with RIKEN and Tokyo University Institute of Medical Science (Department of Genome Preventive Medicine for Social Implementation).

Name

NTT Precision Medicine

Legal name

NTTプレシジョンメディシン株式会社

Website

https://ntt-precisionmedicine.co.jp

Company type

Private

Founded year

2019

Operating status

Operating

Short description

NTT Precision Medicine is a wholly-owned NTT subsidiary that provides genetic testing (Genovision Dock and Genovision PGx), data integration (JPP), cohort analytics, EMR (Mobacaru), and corporate wellness services to Japanese enterprises, medical institutions, and individual consumers.

Ownership category

akta.pro rank

Product category

Precision Medicine and Genetic Testing Services

NAICS

Medical Laboratories (621511), Medical and Diagnostic Laboratories (6215), Medical and Diagnostic Laboratories (62151), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Medical Laboratories (8071), In Vitro & In Vivo Diagnostic Substances (2835), Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Genomic Profiling & Sequencing-Based Precision Medicine (HLAAANAA)

akta.pro secondary industries

Molecular Diagnostics & Genomics Laboratories (HLAFAMAE), Genetic & Genomic Testing (germline, somatic, carrier, pharmacogenomics) (HLAAALAD), Molecular Diagnostics (PCR/qPCR, NGS-based assays) (HLAAALAA), Molecular & Genetic Testing (PCR/NGS/qPCR) (HLAGADAF)

Keywords

• Genetic testing services
• Precision medicine platform
• Pharmacogenomics testing
• Corporate health management
• Electronic medical records

Headquarters

HQ city

Tokyo

HQ country

Japan

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Infrastructure, Supply Chain, Marketing or Sales

Revenue model

1. Corporate employee genetic testing services: NTT Precision Medicine provides Genovision Dock and Genovision PGx as employee health management (健康経営) benefits through corporate health checkup programs. Companies contract with NTT Precision Medicine to offer genetic testing to employees as part of corporate wellness initiatives. Revenue is generated through B2B contracts with employers and health insurance associations.
2. Individual genetic testing via medical institutions: Individual consumers receive genetic testing services (Genovision Dock, Genovision PGx) at partner medical institutions (76 facilities as of July 2026) during health checkups. Results are delivered through the Genovision web portal.
3. Health management consulting services: Health management consulting services (健康経営コンサルティング) are offered to corporations seeking to implement data-driven employee wellness programs, supporting health productivity management objectives.
4. 特定保健指導サービス (Specified Health Guidance): Continuous glucose monitoring and lifestyle intervention programs provided to corporations and healthcare providers for metabolic syndrome prevention, using Abbott FreeStyle Libre 2 sensors and supervised dietary guidance.

Go-to-market motion2 records

Distribution channels3 records

Marketing channels4 records

Core offering

NTT Precision Medicine provides genetic testing services through its Genovision® brand, including Genovision Dock® (disease risk and constitution analysis for ~90 diseases via SNP genotyping) and Genovision PGx (pharmacogenomics analysis for ~70 medications using RIKEN's corePGseq technology). The company also operates the Japan Precision Medicine Platform® (JPP) for clinical-exam-genomic data integration, the Mobacaru Hospital cloud-based electronic medical record system, and corporate health management consulting services.

Product overview

NTT Precision Medicine offers a portfolio of precision medicine products and services centered on its Genovision® genetic testing brand. The core offering comprises two genetic testing services: Genovision Dock® (disease risk and constitution analysis using SNP genotyping of approximately 650,000 markers) and Genovision PGx (pharmacogenomics testing using RIKEN's corePGseq technology covering 18 genes and approximately 70 drugs). Supporting services include the Japan Precision Medicine Platform® (JPP) for data integration, NTTコホート for cohort data services, Mobacaru Hospital electronic medical records (with June 2026 AI document creation option), and a suite of health management services including specific health guidance, corporate health management consulting, and specialized training programs (mental skills, women's health literacy, physical fitness, and carbohydrate control).

Differentiator

Problem solved

Functional benefit

Brands

• Genovision® (ゲノビジョン): Comprehensive genetic testing service brand offering Genovision Dock® for disease risk and constitution analysis, and Genovision PGx for pharmacogenomics testing.
• Genovision Dock® (ゲノビジョン ドック)
• Genovision PGx (ゲノビジョン ピージーエックス)
• Japan Precision Medicine Platform® (JPP)
• Mobacal Hospital (モバカルホスピタル)
• NTT Cohort (NTTコホート)

Products and services

• Genovision® (ゲノビジョン) Comprehensive genetic testing brand offering Genovision Dock® for disease risk and constitution analysis and Genovision PGx for pharmacogenomics testing. Designed for working adults receiving genetic testing through corporate wellness programs and individuals seeking preventive health insights.
• Genovision Dock® (ゲノビジョン ドック) Genetic testing service that analyzes approximately 650,000 SNP markers from blood or saliva samples to predict disease risk for approximately 90 conditions (cancers, lifestyle diseases, brain/neurological conditions, vascular/organ diseases) and physical trait tendencies. Reports relative risk compared to the average Japanese population with prevention behavior recommendations based on global research literature. Delivered to corporate wellness participants and individuals receiving health checkups at partner medical institutions.
• Genovision PGx (ゲノビジョン ピージーエックス) Pharmacogenomics testing service analyzing 18 drug-response-related genes using RIKEN's corePGseq technology to predict drug efficacy and side effect risk tendencies for approximately 70 medications covering lifestyle diseases, neurological conditions, and metabolic disorders. Results interpreted using JCPIC content framework. Aimed at physicians, pharmacists, and patients seeking personalized drug selection.
• Japan Precision Medicine Platform® (JPP) Precision medicine data integration and analytics platform that aggregates and analyzes clinical data, examination data, and other medical/healthcare data to support the realization of precision medicine. Targeted at medical institutions, research institutions, and corporate health programs.
• Mobacaru Hospital (モバカルホスピタル) Cloud-based electronic medical record system for hospitals and clinics. Provides digital clinical workflow management and integrates with precision medicine data. Used by partner medical institutions across Japan.
• NTT Cohort (NTTコホート) Cohort data service utilizing genetic, health checkup, and insurance claims data of employed populations to support research and development in disease prevention and precision medicine. Designed for research institutions and corporate health management programs.
• Specific Health Guidance Service (特定保健指導サービス) Specific health guidance program for metabolic syndrome prevention featuring gentle carbohydrate control (70-130g/day) combined with continuous glucose monitoring using Abbott FreeStyle Libre 2 sensors worn for 2 weeks. Includes smartphone app for real-time glucose data sharing with health advisors. Provided to corporations and healthcare providers.
• Health Management Service (健康経営®サービス) Corporate health management service supporting Japanese companies in implementing health management (健康経営) strategies for employees, including health productivity management objectives and employee wellness program development.
• Health Management Consulting (健康経営®コンサルティング) Health management consulting services offered to corporations seeking to implement data-driven employee wellness programs, supporting health productivity management objectives. Designed for HR leaders and corporate health managers.

Quantifiable outcome

• Genovision Dock analyzes approximately 650,000 SNP sites with ~97% genotyping accuracy
• +3 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability3 records

Feature5 records

Partnerships

Nine partnerships are on record, tiered minor and core.

• 新医療リアルワールドデータ研究機構株式会社 (New Medical Real World Data Research Institute)minorStrategic or Co-development Partner · 12 June 2026Joint data utilization agreement for sharing business partner information (company names, addresses, contact details) for efficient contract management and service provision. Part of NTT Precision Medicine Group's integration of pharmaceutical sales functions.
• PRiME-R Inc.minorStrategic or Co-development Partner · 25 June 2025PRiME-R Inc. is a group company of NTT Precision Medicine. Listed under the group companies section on the company website alongside 株式会社クリニカルサポート (Clinical Support).
• 株式会社クリニカルサポート (Clinical Support)minorStrategic or Co-development Partner · 25 June 2025Clinical Support Co., Ltd. is a group company of NTT Precision Medicine. Listed alongside PRiME-R Inc. as part of the NTT Precision Medicine Group.
• mMEDICIminorGTM or Marketing Partner · 25 June 2025mMEDICI concluded a partnership agreement with NTT Precision Medicine and PRiME-R as announced in June 2025. Details of the partnership scope were not specified in the available source data.
• ジェネシスヘルスケア株式会社 (Genesis Healthcare Co., Ltd.)coreTechnology or Integration · 1 June 2023Genesis Healthcare handles all genetic analysis (genotyping) for both Genovision Dock and Genovision PGx services. They use Illumina Asian Screening Array for SNP genotyping (Genovision Dock) and next-generation sequencing with corePGseq (Genovision PGx). Located at Ebisu Garden Place Tower 26F, Shibuya, Tokyo. Analysis operations began June 2023.
• 理化学研究所 (RIKEN)coreStrategic or Co-development PartnerNTT Precision Medicine has a licensing and co-development relationship with RIKEN for the corePGseq pharmacogenomics technology. RIKEN developed this technology over many years specifically for Japanese patients. Genovision PGx uses corePGseq for high-precision analysis of 18 drug-response-related genes.
• 東京大学医科学研究所 (Tokyo University Institute of Medical Science)coreStrategic or Co-development PartnerNTT and Tokyo University Institute of Medical Science established the 'Department of Genome Preventive Medicine for Social Implementation' (ゲノム予防医学社会実装研究部門) for joint research on disease risk factors and efficient disease prevention methods based on genomic and health checkup data. Genovision Dock's physical trait analysis is based on this joint research. The physical trait component of disease risk reports uses research findings from this collaboration.
• 特定非営利活動法人こどもたちのこどもたちのこどもたちのためにminorStrategic or Co-development PartnerThis NPO is entrusted with creating the disease risk report generation logic for Genovision Dock. They evaluate the quality of research papers on disease risks and genetic factors using GWAS methodology, selecting reliable SNPs for inclusion in the service.
• 日本薬理遺伝学臨床実装コンソーシアム (JCPIC)coreStrategic or Co-development PartnerJCPIC (Japan Clinical Pharmacogenomics Implementation Consortium) provides the content framework for Genovision PGx's drug response interpretation. Based on CPIC (Clinical Pharmacogenetics Implementation Consortium) international guidelines, JCPIC content is reviewed and approved by multiple Japanese physicians for Japan-specific drug dosing guidance.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Market position

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about NTT Precision Medicine